Recently, a number of pharmaceutical companies announced their 2021 results. The People's Daily health client combed and found that core drugs have become the key points driving performance growth.
Novartis: Scucciyuzumab and Sakuba Valsartan have become the keys to driving performance growth
On February 2, Novartis announced its 2021 results, and the scuciyuzumab and sakuba valsartan contributed a total of 8.266 billion US dollars, becoming the most critical drug driving Novartis' performance growth. Following December 2021 becoming the only biologics approved in the U.S. for active tendonitis-related arthritis and active JUVENILE Psoriatic arthritis, scuzidumab also saw strong growth after it was included in the national health insurance directory. Sakubatri valsartan has become the treatment of choice for patients with reduced ejection fraction and heart failure retention, and the two indications of heart failure and hypertension with reduced ejection fraction have been listed in the national medical insurance directory and have taken effect from January 2022.
Novo Nordisk: Smegroide has become the core product of the current situation
On February 2, Novo Nordisk announced its 2021 results, Victoza entered the medical insurance after the rapid release of volume, 2021 sales revenue in China of 1.544 billion DKK (about 1.592 billion yuan). Novo Nordisk's current core products are smeglerutide, of which the oral preparation Rybelsus sales revenue of 4.838 billion DKK (about 769 million US dollars), the subcutaneous injection agent Oasispic sales revenue of 33.705 billion DKK (about 5.359 billion US dollars), subcutaneous injection preparation Wegovy after obtaining FDA approval for its weight loss indications, driving Novo Nordisk to achieve rapid growth in the diet drug market.
AbbVie: The single drug for autoimmune diseases exceeded $20 billion
On February 2, AbbVie announced its 2021 results, autoimmune disease business revenue of 25.284 billion US dollars, a share of 45%, of which, adalimumab in 2021 sales revenue of 20.694 billion US dollars, the annual sales of a single drug exceeded the 20 billion US dollar mark, while the follow-up autoimmune product line is also strongly supplemented, Resalizalumab sales revenue of 2.939 billion US dollars, upatinib sales revenue of 1.65 billion US dollars, as a double insurance. AbbVie sees oncology as the second largest segment outside of autoimmune diseases, with Vinaikera's sales revenue reaching $1.82 billion in 2021, up 36.1% year-on-year.
Gilead: The new three-in-one HIV drug, Betovir, is a core pillar of growth
On February 1, local time, Gilead Science's official website announced the 2021 results, the three-in-one HIV new drug Pitovy is the core pillar product of Gilead's growth, with sales revenue of $8.624 billion in 2021, an increase of 19% year-on-year; remdesivir sales revenue reached $5.56 billion, an increase of 98%; cell therapy sales revenue still grew rapidly and steadily, reaching 871 million, up 43%. Aguilensay became the first inert lymphoma and CAR-T cell therapy to report 5-year survival data for refractory large B-cell lymphoma and show long-term survival benefits, while being approved for marketing in China, with sales revenue of $690 million in 2021, a 23% increase from last year.
Editor-in-charge: Li Yimeng
